# Nyxoah SA > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Nyxoah SA). ## Overview Nyxoah SA is a medical technology company focused on neuromodulation-based treatments for obstructive sleep apnea. Its core product is the Genio system, an implantable therapy designed for patients with moderate to severe OSA, and the company operates from Belgium with commercial reach in the United States and multiple international markets. ## Products & services • Genio system implantable therapy for obstructive sleep apnea • Neuromodulation-based OSA treatment platform • Surgeon training and clinical support for implant centers • Product development and manufacturing for OSA devices - **Implantable OSA Therapy** (80%) — Genio-based neuromodulation systems used to treat obstructive sleep apnea. - **Commercial Device Sales** (15%) — Sales of implanted systems and related components to treatment centers and hospitals. - **Clinical and Training Support** (5%) — Support services tied to device adoption, physician training, and center onboarding. - Genio system implantable therapy for obstructive sleep apnea - Neuromodulation-based OSA treatment platform - Surgeon training and clinical support for implant centers - Product development and manufacturing for OSA devices ## Customers Nyxoah sells into hospitals, ambulatory surgery centers, and specialist sleep/ENT practices that implant and manage treatment for obstructive sleep apnea patients. The buying decision is driven by clinical fit, reimbursement access, physician training, and the ability to offer an alternative to existing OSA therapies. - **Hospitals and ASC implant centers** (primary) — Buy Genio systems and use them to deliver implant-based OSA therapy. - **ENT surgeons and sleep physicians** (primary) — Adopt and recommend the therapy because it expands treatment options for OSA patients. - **Payers and reimbursement systems** (primary) — Do not buy the product directly, but determine whether centers can routinely use it. - **International distributors** (secondary) — Support commercialization in markets where Nyxoah uses partner-led sales. - Hospitals and ambulatory surgery centers implanting the Genio system - ENT surgeons seeking device-based OSA treatment options - Sleep physicians managing moderate to severe OSA patients - Payers and reimbursement systems that influence adoption - Distributor partners in select international markets ## Geography Nyxoah is headquartered in Belgium and has manufacturing, product development, and commercialization activities tied to Europe and the United States. The company has disclosed revenue and market entry across the U.S., Switzerland, the U.K., the Netherlands, the Middle East, and several other European markets, which makes reimbursement and regulatory access central to its geography profile. - **Belgium** (0%) — Corporate and manufacturing base; no revenue share disclosed. - **United States** (0%) — Key commercial market; no total revenue share disclosed. - **Europe** (0%) — Includes revenue from Switzerland, the U.K., the Netherlands and other European markets. - **Middle East** (0%) — Commercialized through distributors in selected countries. - Belgium is the operating base for manufacturing and product development - United States is a key commercialization market for Genio - Europe remains the main clinical and reimbursement foundation - International rollout includes Switzerland, the U.K., and the Netherlands - Middle East commercialization is conducted through a distributor model ## Strategy Nyxoah’s strategy centers on building a clinical ecosystem around Genio, expanding reimbursement coverage, and widening the installed base of implanting centers. The company is also scaling manufacturing and commercialization capacity to support U.S. growth and broader international adoption while preserving product and clinical credibility. - **U.S. commercialization rollout** (short-term) — The U.S. is a major market for OSA devices and requires training, adoption, and reimbursement support. - **Reimbursement expansion** (medium-term) — Coverage decisions determine whether therapy can be used routinely and at scale. - **Manufacturing scale-up** (medium-term) — Higher capacity is needed to meet demand and support a broader international footprint. - **Clinical evidence generation** (long-term) — Post-approval studies and clinical outcomes support physician adoption and payer confidence. - Expand U.S. commercialization through phased center-by-center rollout - Broaden reimbursement access in Europe and other international markets - Build a Center of Excellence model around ENT and sleep specialists - Increase manufacturing capacity to support expected demand growth - Use clinical evidence to deepen acceptance of implantable OSA therapy ## Risks Nyxoah’s business depends on regulatory approvals, reimbursement decisions, and successful physician adoption of a relatively specialized implantable therapy. The company also faces execution risk as it scales manufacturing and commercialization across multiple geographies, while demand can vary by country-specific coverage and clinical practice patterns. - **Reimbursement dependency** [high] — OSA implant adoption is highly sensitive to payer coverage and national reimbursement pathways. - **Regulatory execution** [high] — The product must maintain approvals and satisfy post-approval clinical requirements. - **Commercial adoption risk** [medium] — Physician training and center conversion are needed before recurring use can build. - **Manufacturing and supply chain execution** [medium] — Device supply must scale reliably while preserving quality and regulatory compliance. - **Clinical evidence risk** [medium] — Future study results can influence treatment positioning and market acceptance. - Reimbursement delays can slow adoption and limit routine use - U.S. commercialization depends on effective surgeon and center onboarding - Manufacturing scale-up must keep pace with demand and quality requirements - Clinical study outcomes can affect physician and payer confidence - International expansion depends on country-by-country regulatory access ## Accounting Nyxoah’s reported numbers are shaped by judgment around development-stage costs, capitalization policies, and the timing of device revenue recognition as commercialization expands. As a medical device company with multi-country operations, it also has to manage estimates for clinical programs, manufacturing-related costs, and any impairment or non-GAAP adjustments tied to its technology platform. - **Revenue recognition timing** — Affects quarterly comparability and launch-period revenue patterns - **Capitalized development costs** — Affects operating expense presentation and cash burn analysis - **Clinical and regulatory study costs** — Affects research expense and liability accruals - **Intangible asset impairment** — Can create non-cash charges if assumptions weaken - Revenue timing matters because device sales can be lumpy by launch phase - Development and manufacturing costs affect capitalization and expense recognition - Clinical study spending can create period-to-period volatility - Non-GAAP adjustments exclude depreciation, amortization, and share-based pay - Impairment and judgmental estimates can affect intangible asset carrying values --- *Last updated: 2026-09-28T12:13:29.397151+00:00*